Experience

• 2021- Director, International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University
• 2021- Director, The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University
• 2019- Associate Professor, Graduate Institute of Biomedical Informatics, Taipei Medical University
• 2012-2018 Associate professor, the Ph.D. Program for translational medicine, Taipei Medical University, Taipei, Taiwan
• 2012-2018 Assistant professor, the Ph.D. Program for translational medicine, Taipei Medical University, Taipei, Taiwan
• 2011 Postdoctoral Fellow, Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan
• 2008-2009 Research scholar, Department of Pathology, University of Rochester, Rochester, NY, U.S.A.
• 2007-2008 Graduate Student Study Abroad Program of NSC in the University of Rochester, U.S.A.
• 2002-2004Teaching assistant, Department of Biochemistry and Molecular Biology, National ChengKung University, Tainan, Taiwan

There are four projects in our lab:

1.  Antibody-Drug Conjugates (ADCs): Precision Weapons against Cancer

Antibody-drug conjugates (ADCs) represent a revolutionary approach in targeted cancer therapy. These innovative molecules combine the specificity of monoclonal antibodies with the potency of chemotherapeutic drugs, enabling selective and effective destruction of cancer cells while minimizing damage to healthy tissues. Through precise targeting of CEACAM6 (a tumor antigen), ADCs offer a promising strategy to enhance the efficacy and reduce the side effects of traditional chemotherapy, opening new avenues in the fight against cancer. In addition, the single-chain antibody-drug conjugate will be a next-generation ADC that is currently developed in our lab.

2. Galectin Roles in Inflammatory and Fibrotic Diseases: Deciphering Disease Mechanisms

Galectins, a family of carbohydrate-binding proteins, have garnered attention for their diverse roles in inflammatory and fibrotic diseases. From modulating immune responses to influencing tissue remodeling, galectins play a multifaceted role in various pathological conditions. We are using glycobiology methodologies to unravel the intricate network of galectin/glycoprotein interactions to gain insights into disease mechanisms and identify potential therapeutic interventions that could alleviate the burden of inflammatory and fibrotic disorders.

3. Risk Assessment of Oral Premalignant Lesions: Paving the Way for Early Intervention

Oral premalignant lesions serve as critical indicators of potential oral cancer development. Rigorous research in this field focuses on developing accurate risk assessment tools to identify high-risk lesions and predict their progression to malignancy. By harnessing the power of molecular markers, imaging technologies, and clinical parameters, we aim to enhance early detection and intervention strategies, ultimately improving patient outcomes and survival rates. In addition, through the omics study, we are also investigating the mecahnisms that induces the transformation of oral premalignant lesions.

4. Cell Therapy for Acute Lung Injury(ALI)-indcued fibrosis

Cell therapy has emerged as a promising avenue for addressing acute lung injury, a life-threatening condition with limited treatment options. Stem cells and other cell types are being explored for their potential to promote tissue repair, reduce inflammation, and enhance lung function. We utilized mesenchymal stem cells (MSC) to treat LPS-induced acute lung injuries and fibrosis. Using Omics and cellular assays, we are investigatign the inmmune modulation ability and anti-fibrotic effect of MSC on ALI.